Alan Trounson, PhD, MSc, on New Frontiers in Allogeneic Cell Therapy

Video

The chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.

“We switched our focus to allogeneic CAR therapies because we felt this was the future in the area. I'm a stem cell biologist having developed embryonic stem cells, and to use an allogeneic cancer therapy to treat hundreds if not thousands of patients with the same product is very attractive [and it would] reduce the cost dramatically if we're able to do that.”

Although autologous chimeric antigen receptor T-cell (CAR-T) therapies have shown great success in treating blood cancers, many companies are now pursuing the development of allogeneic CAR-T therapies in order to overcome certain limitations of the autologous approach.

In an interview with CGTLive, Alan Trounson, PhD, MSc, chief executive officer and executive director of Cartherics, discussed the company’s decision to focus on allogeneic cell therapies and several of the investigational products currently in the company’s pipeline. He spoke about the decision to generate induced pluripotent stem (iPS) cells from umbilical cord samples. Trounson emphasized that these cell lines are immortal and can be directed to develop into any immune cell type, allowing for great versatility. To illustrate this, he noted that Cartherics is using its iPS cell platform to develop natural killer (NK) cell, T-cell, and macrophage cell therapies with potential indications for solid tumor types including ovarian, gastric, prostate, pancreatic, liver, and kidney cancers.

In addition to discussing several of the company’s near-term pipeline products, Trounson also discussed other areas of possible development for the future. In particular, he spoke about the potential for introducing a memory component to cell therapies to help prevent against future occurrences of cancer.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.